AU2001232304A1 - Eosinophil-specific apoptosis inducer - Google Patents

Eosinophil-specific apoptosis inducer

Info

Publication number
AU2001232304A1
AU2001232304A1 AU2001232304A AU3230401A AU2001232304A1 AU 2001232304 A1 AU2001232304 A1 AU 2001232304A1 AU 2001232304 A AU2001232304 A AU 2001232304A AU 3230401 A AU3230401 A AU 3230401A AU 2001232304 A1 AU2001232304 A1 AU 2001232304A1
Authority
AU
Australia
Prior art keywords
eosinophil
apoptosis inducer
specific apoptosis
specific
inducer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001232304A
Inventor
Nobuo Hanai
Masamichi Koike
Kazuyasu Nakamura
Kenya Shitara
Emi Shoji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of AU2001232304A1 publication Critical patent/AU2001232304A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2001232304A 2000-02-15 2001-02-15 Eosinophil-specific apoptosis inducer Abandoned AU2001232304A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000036671 2000-02-15
JP2000-36671 2000-02-15
PCT/JP2001/001077 WO2001060405A1 (en) 2000-02-15 2001-02-15 Eosinophil-specific apoptosis inducer

Publications (1)

Publication Number Publication Date
AU2001232304A1 true AU2001232304A1 (en) 2001-08-27

Family

ID=18560688

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001232304A Abandoned AU2001232304A1 (en) 2000-02-15 2001-02-15 Eosinophil-specific apoptosis inducer

Country Status (5)

Country Link
US (1) US7404953B2 (en)
EP (1) EP1266663A4 (en)
AU (1) AU2001232304A1 (en)
CA (1) CA2402477A1 (en)
WO (1) WO2001060405A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2420835T3 (en) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedure to control the activity of immunofunctional molecules
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
ATE541585T1 (en) * 2004-10-28 2012-02-15 Kyowa Hakko Kirin Co Ltd ANTIBODIES TO IL-5 RECEPTOR FOR USE IN THE TREATMENT OF ENDOMETRIOSIS.
EP2068927B1 (en) * 2007-05-14 2015-10-21 MedImmune, LLC Methods of reducing eosinophil levels
RU2676333C2 (en) 2013-08-12 2018-12-28 Астразенека Аб Methods for reducing exacerbation rates of asthma using of benralizumab
SG11201600483QA (en) 2013-08-12 2016-02-26 Medimmune Llc Methods for increasing forced expiratory volume in asthmatics using benralizumab
JP6803229B2 (en) 2013-08-12 2020-12-23 アストラゼネカ アクチボラグ How to improve asthma symptoms with benlaritumab
JP2016534996A (en) * 2013-10-15 2016-11-10 メディミューン，エルエルシー Methods for treating chronic obstructive pulmonary disease using benralizumab
JP2018538249A (en) 2015-11-04 2018-12-27 アストラゼネカ アクチボラグ Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil targeted therapeutics in eosinophilic diseases
WO2018139404A1 (en) * 2017-01-24 2018-08-02 協和発酵キリン株式会社 Therapeutic or prophylactic agent and treatment or prevention method for radiation sickness

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465616B1 (en) * 1994-04-08 2002-10-15 Bresagen Limited Interleukin-5 antagonist
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
CA2205007C (en) 1995-09-11 2010-12-14 Masamichi Koike Antibody against human interleukin-5 receptor .alpha. chain
AU7132098A (en) 1997-04-18 1998-11-13 Tanox Biosystems, Inc. Il-5r antagonists for treatment of inflammation, asthma and other allergic diseases

Also Published As

Publication number Publication date
EP1266663A1 (en) 2002-12-18
CA2402477A1 (en) 2001-08-23
US20040136996A1 (en) 2004-07-15
WO2001060405A1 (en) 2001-08-23
EP1266663A4 (en) 2003-07-23
US7404953B2 (en) 2008-07-29

Similar Documents

Publication Publication Date Title
AU2001262237A1 (en) Reflector
AU2001231752A1 (en) Cook-top
AU2001260327A1 (en) Chair
AU2000267458A1 (en) Hypercomputer
AU2001241100A1 (en) Polypeptide inducing apoptosis
AU2001253666A1 (en) Distributed rendering
AU2001274548A1 (en) Syringe
AU2001280598A1 (en) Anti-occlusion catheter
AU2965600A (en) Interleukin-20
AU2001232304A1 (en) Eosinophil-specific apoptosis inducer
AU2001230605A1 (en) Apoptosis inhibitor
AU2001232244A1 (en) Drug comprising combination
AU2001236929A1 (en) Surface treatment
AU2002210379A1 (en) Subtilase variants
AU2001275723A1 (en) Bougie
AU2002222557A1 (en) Interferon therapeutic effect-potentiating agents
AU2001277857A1 (en) Tumor necrosis factor-gamma
AU2002241767A1 (en) Concurrent-multitasking processor
AU2001264445A1 (en) Reverse-running pump
AU2001252200A1 (en) Chair
AU2001264350A1 (en) Multi-scroll pump
AU2001295815A1 (en) Multiple purpose catheter
AU2002223457A1 (en) Pump
AU2002221890A1 (en) Effect light
EP1274932B8 (en) Pump